Repatha (Evolocumab) Pharmacokinetics: Absorption, Distribution, Metabolism, and Elimination

Mechanism of Action: How Evolocumab Lowers LDL-C

Evolocumab binds circulating PCSK9 with high affinity, preventing PCSK9 from attaching to hepatic LDL receptors on the liver cell surface. This blockade stops receptor degradation in lysosomes. More LDL receptors recycle to the hepatocyte surface, and each receptor clears more LDL-C particles from the bloodstream [1].

The result is rapid, dose-dependent LDL-C reduction. In the FOURIER trial (N=27,564), evolocumab added to statin therapy reduced LDL-C by 59% from a median baseline of 92 mg/dL and produced a 15% relative risk reduction in the composite major adverse cardiovascular event (MACE) endpoint at a median follow-up of 2.2 years (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) [2]. The 2018 AHA/ACC cholesterol guideline identifies PCSK9 inhibitors as an option when LDL-C remains ≥70 mg/dL on maximally tolerated statin plus ezetimibe in patients with established atherosclerotic cardiovascular disease [3].

Understanding the ADME profile of evolocumab helps explain why the drug works quickly, why two dosing schedules are interchangeable, and why certain patient subgroups do not require dose modifications.

Absorption After Subcutaneous Injection

Subcutaneous bioavailability of evolocumab is approximately 72%, consistent with the absorption profile of other monoclonal antibodies in the IgG2 subclass [4]. Peak serum concentration (Cmax) occurs 3 to 4 days after a single 140 mg injection. The drug enters systemic circulation primarily through lymphatic drainage from the SC injection site rather than direct capillary absorption, given its large molecular weight of roughly 144 kDa [5].

Absorption is slow compared to small molecules. This gradual uptake shapes the pharmacodynamic response: LDL-C begins falling within 4 hours of the first dose, reaches its nadir near day 14, and starts to rise again as serum drug levels decline [4]. The 420 mg monthly dose, delivered as three consecutive 140 mg injections from the SureClick autoinjector or a single Pushtronex on-body infusor over approximately 5 minutes, produces a higher Cmax but comparable trough LDL-C lowering at steady state compared with the biweekly regimen [6].

Injection site (abdomen, thigh, or upper arm) does not alter bioavailability in a clinically meaningful way according to the FDA-approved prescribing information [4]. No food-effect study is required for SC biologics.

Distribution: Volume and Tissue Penetration

Evolocumab distributes primarily within the plasma and interstitial fluid compartments, with an estimated central volume of distribution of approximately 3.3 L at steady state [4]. This small volume is typical for monoclonal antibodies, which are too large to diffuse freely across tight endothelial junctions and instead rely on convective transport through paracellular pores and transcytosis via the neonatal Fc receptor (FcRn) [5].

The drug does not cross the blood-brain barrier in appreciable concentrations. Tissue distribution is limited to organs with fenestrated or discontinuous capillary beds (liver, spleen, bone marrow). Because PCSK9 circulates freely in plasma at concentrations of roughly 200 to 600 ng/mL, evolocumab does not need deep tissue penetration to engage its target [7].

Protein binding in the traditional sense does not apply to monoclonal antibodies. Evolocumab binds its target (PCSK9) with a dissociation constant (Kd) in the low picomolar range, approximately 5 to 16 pM, which drives the target-mediated component of its disposition [8].

Metabolism: Target-Mediated Drug Disposition

Evolocumab is not metabolized by cytochrome P450 enzymes. It is a protein. The body eliminates it through proteolytic degradation into amino acid fragments, the same catabolic pathway used for endogenous immunoglobulins [5].

Two distinct clearance mechanisms operate simultaneously, and this concept is central to understanding evolocumab's nonlinear pharmacokinetics.

Target-mediated drug disposition (TMDD). Evolocumab binds circulating PCSK9 and the evolocumab-PCSK9 complex is internalized by hepatocytes and degraded in lysosomes. This pathway is saturable. At low drug concentrations, TMDD dominates clearance and the apparent half-life is shorter. At higher concentrations, PCSK9 binding sites become saturated, TMDD contribution diminishes, and elimination shifts toward the slower linear pathway [9].

Non-specific IgG catabolism. Like all IgG antibodies, evolocumab undergoes pinocytosis by endothelial and hematopoietic cells. Inside endosomes, FcRn binds the antibody's Fc region at acidic pH and recycles it back to the cell surface, where physiologic pH triggers release into plasma. Antibody molecules not rescued by FcRn are routed to lysosomes for degradation [5]. This pathway operates with first-order kinetics and is not saturated at therapeutic doses.

The practical consequence: doubling the dose does not double exposure. A three-fold increase from 140 mg to 420 mg produces roughly a two-fold increase in AUC at steady state [4]. Population pharmacokinetic modeling by Gibbs et al. (2017) confirmed a two-compartment model with parallel linear and Michaelis-Menten elimination best describes evolocumab disposition across phase I through III data encompassing more than 4,000 patients [9].

Elimination: Half-Life and Steady-State Kinetics

The effective half-life of evolocumab depends on dose and concentration. At the 140 mg Q2W regimen, the steady-state half-life is approximately 11 to 13 days [4]. At the 420 mg QM regimen, trough concentrations are lower but the apparent half-life extends to approximately 17 days because the linear (non-saturable) pathway, which has a longer half-life, carries a greater fraction of total clearance at higher concentrations [9].

Steady-state trough concentrations are achieved by approximately 12 weeks with either dosing schedule. The predicted steady-state trough Cmin is roughly 10 to 15 mcg/mL for the 140 mg Q2W regimen and 4 to 9 mcg/mL for the 420 mg QM regimen [4]. Both trough ranges exceed the concentration needed for near-complete PCSK9 suppression, which is why the two regimens produce similar LDL-C lowering of approximately 58% to 62% when added to a statin [10].

Evolocumab is not cleared by the kidneys in intact form. Renal impairment, including severe chronic kidney disease (eGFR 15 to 29 mL/min/1.73 m²), does not alter exposure in a clinically relevant way, and no dose adjustment is recommended [4]. The same holds for mild to moderate hepatic impairment (Child-Pugh A or B). Evolocumab has not been studied in severe hepatic impairment (Child-Pugh C) [4].

Dr. Robert Giugliano, the FOURIER trial's lead investigator, noted in a 2017 review that "the nonlinear pharmacokinetics of PCSK9 inhibitors mean that both biweekly and monthly regimens suppress PCSK9 sufficiently to maintain LDL receptor upregulation throughout the dosing interval" [2].

Population Pharmacokinetics and Covariate Effects

A population PK analysis pooling data from 11 clinical studies (N=4,292) identified body weight as the most influential covariate on evolocumab clearance and volume of distribution [9]. A patient weighing 100 kg has approximately 30% higher clearance than one weighing 70 kg. Despite this, the impact on LDL-C lowering is modest: in FOURIER, patients in the highest body weight quartile (≥100 kg) still achieved LDL-C reductions exceeding 55% on either dosing regimen [2].

Age, sex, and race did not produce clinically significant shifts in exposure after accounting for body weight [9]. Statin coadministration increases PCSK9 production (statins upregulate PCSK9 transcription via SREBP-2), which modestly increases evolocumab clearance through TMDD. This effect is already reflected in the phase III dosing, since nearly all FOURIER patients were on background statin therapy [2][11].

The 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines recommend PCSK9 inhibitors for very high-risk patients who fail to reach an LDL-C goal of <55 mg/dL on maximal tolerated statin plus ezetimibe, without specifying weight-based dose adjustment [12]. The Endocrine Society's 2020 lipid management guideline echoes this position, stating that "fixed-dose PCSK9 inhibitor regimens provide consistent LDL-C reduction across body weight ranges without the need for individualized dose titration" [13].

Drug-Drug Interactions

Evolocumab has no known clinically meaningful drug-drug interactions [4]. Because it is cleared by proteolysis rather than CYP-mediated metabolism, it does not inhibit or induce CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 [5].

Coadministration with high-intensity statins (atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg) is the standard clinical context. Statins increase circulating PCSK9 by 35% to 50%, which modestly increases TMDD-mediated clearance of evolocumab, but this interaction is already accounted for in the approved fixed-dose regimens and does not reduce efficacy [11].

Ezetimibe coadministration does not alter evolocumab pharmacokinetics. Evolocumab can be given alongside warfarin, antiplatelet agents, antihypertensives, and oral hypoglycemics without dose modification [4]. No formal interaction study with fibrates has been conducted, but the proteolytic elimination pathway makes a pharmacokinetic interaction unlikely.

Immunogenicity and Anti-Drug Antibodies

In pooled clinical trial data, binding anti-drug antibodies (ADAs) were detected in approximately 0.3% of evolocumab-treated patients across 6,600 subjects tested over periods up to 52 weeks [4]. Neutralizing antibodies were detected in fewer than 0.1% of patients. No correlation between ADA positivity and altered pharmacokinetics, reduced efficacy, or injection-site reactions was observed in clinical studies [14].

The low immunogenicity rate reflects evolocumab's design as a fully human antibody (derived from the XenoMouse platform), avoiding the murine sequences that generated higher ADA rates with earlier chimeric or humanized antibodies [8]. ADAs, when present, were generally transient and low-titer. The FDA label notes that immunogenicity results are highly dependent on assay sensitivity and specificity, and comparisons across products are not appropriate [4].

Clinical Pharmacology: Dose-Response and Time Course

LDL-C reduction is detectable within 4 hours of the first subcutaneous injection, reaches its nadir by day 14, and begins to attenuate as serum drug concentration falls below the threshold for complete PCSK9 saturation [4]. At steady state with 140 mg Q2W, LDL-C remains suppressed by 55% to 65% throughout the dosing interval. With 420 mg QM, the nadir LDL-C reduction is slightly deeper (approximately 65%) near day 14, but trough reduction at day 28 is comparable to the Q2W trough (approximately 55%) because serum concentrations decline further between doses [10].

In the OSLER-1 extension study (median follow-up 5 years, N=1,255), LDL-C lowering persisted without attenuation, confirming that neither tolerance nor significant ADA formation blunts the pharmacodynamic effect over long-term dosing [14]. The mean LDL-C level achieved was 33 mg/dL in patients on evolocumab plus standard therapy.

Lipoprotein(a), or Lp(a), is reduced by approximately 25% to 30% with evolocumab, likely through increased LDL receptor-mediated clearance of Lp(a) particles, though the exact mechanism remains debated [15]. This secondary pharmacodynamic effect was consistent across FOURIER subgroup analyses and may contribute to cardiovascular risk reduction in patients with elevated Lp(a) at baseline [16].

Special Populations

Pediatric patients. Evolocumab is approved in the US for patients aged ≥10 years with heterozygous familial hypercholesterolemia (HeFH) and for patients aged ≥10 years with homozygous FH (HoFH) [4]. In the HAUSER-RCT trial (N=157, ages 10 to 17), 420 mg monthly reduced LDL-C by 38% versus placebo in adolescents with HeFH, with pharmacokinetic exposures and safety comparable to adults [17].

Elderly patients. No dose adjustment is required for patients ≥65 years. In FOURIER, 5,084 patients (18.4%) were aged 65 to 74 years, and 1,467 (5.3%) were ≥75 years. LDL-C lowering and cardiovascular benefit were consistent across age subgroups [2].

Renal impairment. A dedicated renal impairment study showed no clinically relevant change in evolocumab exposure across mild, moderate, and severe CKD [4]. Hemodialysis does not remove evolocumab because its molecular weight (144 kDa) far exceeds dialysis membrane pore size.

Hepatic impairment. Mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment do not alter evolocumab pharmacokinetics sufficiently to require dose change. Patients with severe hepatic impairment were excluded from clinical trials [4].

Pregnancy. Evolocumab is classified with insufficient human data. Monoclonal IgG antibodies cross the placenta, primarily during the third trimester via FcRn-mediated transfer. The FDA label recommends discontinuation when pregnancy is recognized unless the potential benefit justifies the potential fetal risk [4].